Laura Stanbery

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande et al. · The Lancet Oncology · 2020 · 112 citations

Medicine, Immunology, Gynecology +6

Adenomatous polyposis coli in cancer and therapeutic implications

Olivia Noe, Louis Filipiak, Rachel Royfman et al. · Oncology Reviews · 2021 · 38 citations · Full text

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer

Rodney P. Rocconi, Bradley J. Monk, Adam Walter et al. · Gynecologic Oncology · 2021 · 35 citations

Radiation Oncology, Homologous Recombination Proficient, Cell Therapy +8

High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma

Laura Stanbery, Nisha J. D’Silva, Julia S. Lee et al. · Translational Oncology · 2010 · 28 citations · Full text

Poor Clinical Outcomes, Immunology, Pathology +17

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Rodney P. Rocconi, Erin Stevens, Justin Bottsford-Miller et al. · Cancer Gene Therapy · 2021 · 23 citations

Medicine, Cancer Management, Principle Study +7